IRIS
PERUCCA, EMILIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.802
AS - Asia 8.542
EU - Europa 7.014
SA - Sud America 968
AF - Africa 130
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 11
Totale 28.487
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.601
CN - Cina 4.974
SG - Singapore 1.833
IE - Irlanda 1.768
UA - Ucraina 1.364
HK - Hong Kong 975
DE - Germania 818
BR - Brasile 800
RU - Federazione Russa 780
FI - Finlandia 618
SE - Svezia 452
GB - Regno Unito 419
IT - Italia 355
VN - Vietnam 248
FR - Francia 151
CA - Canada 123
IN - India 122
JP - Giappone 60
AR - Argentina 57
PL - Polonia 54
MX - Messico 53
NL - Olanda 47
BD - Bangladesh 43
IQ - Iraq 41
ZA - Sudafrica 40
ID - Indonesia 34
BE - Belgio 33
TR - Turchia 31
AT - Austria 26
ES - Italia 25
PK - Pakistan 21
VE - Venezuela 21
EC - Ecuador 20
LT - Lituania 19
UZ - Uzbekistan 19
CL - Cile 18
IL - Israele 18
AE - Emirati Arabi Uniti 17
CO - Colombia 17
AU - Australia 16
EG - Egitto 16
CZ - Repubblica Ceca 15
PE - Perù 15
SA - Arabia Saudita 15
KE - Kenya 14
IR - Iran 13
MU - Mauritius 13
SI - Slovenia 12
TN - Tunisia 10
EU - Europa 9
KR - Corea 9
AZ - Azerbaigian 8
DZ - Algeria 8
PY - Paraguay 8
SK - Slovacchia (Repubblica Slovacca) 8
JO - Giordania 7
MA - Marocco 7
PA - Panama 6
CH - Svizzera 5
MY - Malesia 5
NP - Nepal 5
RO - Romania 5
TW - Taiwan 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
EE - Estonia 4
GR - Grecia 4
KG - Kirghizistan 4
LV - Lettonia 4
MD - Moldavia 4
NO - Norvegia 4
PS - Palestinian Territory 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BO - Bolivia 3
BY - Bielorussia 3
CR - Costa Rica 3
HN - Honduras 3
KZ - Kazakistan 3
LB - Libano 3
NZ - Nuova Zelanda 3
PH - Filippine 3
AL - Albania 2
AO - Angola 2
BG - Bulgaria 2
BH - Bahrain 2
DK - Danimarca 2
ET - Etiopia 2
GF - Guiana Francese 2
GN - Guinea 2
HR - Croazia 2
HU - Ungheria 2
IS - Islanda 2
JM - Giamaica 2
LK - Sri Lanka 2
LU - Lussemburgo 2
ML - Mali 2
NI - Nicaragua 2
Totale 28.457
Salva come PNG Salva come JPEG
Città #
Chandler 1.861
Dublin 1.768
Jacksonville 1.660
Nanjing 1.224
Dallas 1.072
Hong Kong 972
Singapore 782
Ashburn 769
Boardman 603
Beijing 529
Nanchang 472
Princeton 448
Lawrence 417
Wilmington 412
Shenyang 360
Changsha 354
Hebei 347
Jiaxing 279
Medford 268
Los Angeles 264
Tianjin 216
Hangzhou 194
Ann Arbor 175
Buffalo 174
Redondo Beach 164
Helsinki 159
Woodbridge 126
Moscow 113
Milan 102
Shanghai 99
Fairfield 91
Ho Chi Minh City 91
New York 87
Saint Petersburg 85
Houston 77
Norwalk 71
Verona 71
São Paulo 70
Munich 67
The Dalles 63
Chicago 58
Toronto 58
Hanoi 56
Tokyo 53
Seattle 52
Cambridge 51
San Francisco 49
Council Bluffs 48
Brooklyn 40
Columbus 40
Warsaw 40
Guangzhou 37
Zhengzhou 35
Brussels 33
Des Moines 32
Kunming 31
London 29
Pavia 28
Turku 28
Falls Church 27
Jinan 27
Johannesburg 26
Chennai 25
Falkenstein 25
Nuremberg 25
Pune 25
Dearborn 23
Orem 22
Charlotte 21
Montreal 21
Taizhou 20
Atlanta 19
Denver 19
Rio de Janeiro 19
Santa Clara 19
Curitiba 18
Belo Horizonte 17
Piscataway 17
Washington 17
Phoenix 16
Mexico City 15
Secaucus 15
Auburn Hills 14
Baghdad 14
Manchester 14
Stockholm 14
Tashkent 14
Boston 13
Campinas 13
Frankfurt am Main 13
Guarulhos 13
Rome 13
Amsterdam 12
Changchun 12
Hefei 12
Ljubljana 12
Mumbai 12
Ningbo 12
San Jose 12
Wuhan 12
Totale 18.663
Salva come PNG Salva come JPEG
Nome #
A simple and rapid HPLC-UV method for the determination of retigabine in human plasma 148
No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk—An analysis of Finnish health register and German health insurance data 147
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma 142
A multiparametric investigation of daytime sleepiness and psychomotor functions in epileptic patients treated with phenobarbital and sodium valproate: a comparative controlled study 142
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. 141
Alterazioni del campo visivo in soggetti epilettici in trattamento cronico con vigabatrin. 134
Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbamazepine in healthy women 134
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. 130
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. 130
Low risk pragmatic trials do not always require participants' informed consent 128
A Double-Blind, Placebo-Controlled Study on the Effect of Vigabatrin on In Vivo Parameters of Hepatic Microsomal Enzyme Induction and on the Kinetics of Steroid Oral Contraceptives in Healthy Female Volunteers 127
A Prospective study on the effects of antiepileptic drugs on the human foetus: The European Registry initiative 125
A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG, 122
Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. 118
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. 116
Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. on behalf of the SOPHIE Study Group. 115
A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. 115
Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. 114
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry 112
A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. 110
A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy 104
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. 102
Concentrations of L-dopa in plasma and plasma ultrafiltrates. 102
Novel Medications for Epilepsy 102
Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age 102
Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. 102
Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. 101
ILAE Official Report: A practical clinical definition of epilepsy 101
Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. 99
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.SOPHIE Study Group. 99
Increased Apparent Oral Clearance of Valproic Acid during Intake of Combined Contraceptive Steroids in Women with Epilepsy 98
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine sources of variability and preliminary observations on relations with clinical response. 97
Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers 97
Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug 97
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. 97
Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience 96
2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction 96
Basal Ganglia Dysmorphism in Patients With Aicardi Syndrome 96
Clinical pharmacokinetics of fluvoxamine. 95
Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (Oxford) 51, 1069-1077, 2010 95
Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring 95
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy 94
A web-based algorithm to rapidly classify seizures for the purpose of drug selection 94
Influence of aging on serum phenytoin concentrations: A pharmacokinetic analysis based on therapeutic drug monitoring data. 93
Effects of phenytoin on the in vivo kinetics of thiamine and its phosphoesters in rat nervous tissues 93
Daytime sleepiness in healthy university students: A multiparametric study 93
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). 93
The new antiepileptic drugs: Pharmacological and clinical aspects. 92
Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects 92
Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: A reappraisal 12 years after a first survey 92
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Commentary. 92
Epilessia nell'anziano:dati dai registri di un centro neurologico. 91
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. 91
Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: a open, prospective, long-term study 90
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation 90
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. 89
Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study. 89
Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma 89
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction 88
Overtreatment in epilepsy: adverse consequences and mechanisms. 88
Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers. 88
A new classification is born 88
THE INFLUENCE OF OLD AGE AND ENZYME INDUCING COMEDICATION ON THE PHARMACOKINETICS OF VALPROIC ACID AT STEADY STATE: A CASE-MATCHED EVALUATION BASED ON THERAPEUTIC DRUG MONITORING DATA. 88
Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. 88
A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy 88
Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. 88
Erratum The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (Open Prospective Randomized Long-term Effectiveness) trial (Epilepsia (2014) 55 (893-900) 87
The remarkable story of valproic acid 87
CYP2D6-related oxidation polymorphism in Italy 87
The management of refractory idiopathic epilepsies 86
Revisiting phenobarbital for epilepsy. 86
Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects 86
Epilepsy: new advances. 86
DIFFERENTIAL-EFFECTS OF VALPROIC ACID AND ENZYME-INDUCING ANTICONVULSANTS ON NIMODIPINE PHARMACOKINETICS IN EPILEPTIC PATIENTS 86
Pharmacokinetic variability of new antiepileptic drugs at different ages. 85
When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy. 85
Farmacocinetica delle benzodiazepine. 85
What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? 84
Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. 84
Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries 83
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. 83
Gender issues in antiepileptic drug treatment 83
Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. 83
Daytime sleepiness in epileptic patients on long-term monotherapy: MSLT, clinical and psychometric assessment 83
ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology 83
Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe 83
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. 83
Role of valproate across the ages. Treatment of epilepsy in the elderly 82
Anticonvulsants 82
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction 82
Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry 82
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes 82
Improving Epilepsy for Life: editorial comment. 81
Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response 81
Topiramate pharmacokinetics in children and adults with epilepsy: A case-matched comparison based on therapeutic drug monitoring data. 81
Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial 81
Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation 80
Vigabatrin and epilepsy. Lessons learned. 80
Adverse drug interactions in epilepsy 80
A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV) 80
Totale 9.716
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.192
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.192
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.573 0 0 0 0 0 323 7 400 78 351 316 98
2021/20221.632 31 5 64 21 20 36 27 101 100 18 275 934
2022/20235.273 641 314 37 471 518 593 0 355 2.110 25 136 73
2023/20241.577 222 281 58 137 170 413 30 107 11 45 60 43
2024/20254.438 141 480 126 178 74 186 145 366 978 166 477 1.121
2025/20265.856 786 1.085 1.420 1.059 1.177 329 0 0 0 0 0 0
Totale 28.866